Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial

Tao Jiang, Shengxiang Ren, Luonan Chen et al.|Signal Transduction and Targeted Therapy|2021

Cited by 94